Expression of MU, KAPPA, and delta opioid receptor messenger RNA in the human CNS: A 33P in situ hybridization study

Neuroscience

Volumn 88, Issue 4, 1999, Pages 1093-1135

  Peckys, D ^a   Landwehrmeyer, G B ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Brain; Human; In situ hybridization; Messenger RNA; Opioid receptors; Phosphorus radioisotopes

Indexed keywords

DELTA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR; MESSENGER RNA; MU OPIATE RECEPTOR;

ADULT; AGED; ARTICLE; BRAIN; BRAIN REGION; CENTRAL NERVOUS SYSTEM; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; MALE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RNA ANALYSIS; TISSUE DISTRIBUTION;

ADULT; AGED; BRAIN; FEMALE; HISTOCYTOCHEMISTRY; HUMANS; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; PHOSPHORUS RADIOISOTOPES; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU; RNA, MESSENGER; SPINAL CORD; TISSUE DISTRIBUTION;

EID: 0032889771     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(98)00251-6     Document Type: Article

References (205)

1. Alreja M., Aghajanian G. K. QX-314 blocks the potassium but not the sodium-dependent component of the opiate response in locus coeruleus neurons. Brain Res. 639:1994;320-324.
2. Anton B., Husain M., Kaufman D., Stickney E., Keith D. J. J. E. C., Miotto K. Localization of mu, delta and kappa opioid receptor mRNAs in human brain. Regul. Pept. 54:1994;11-12.
3. Arvidsson U., Dado R. J., Riedl M., Lee J. H., Law P. Y., Loh H. H., Elde R., Wessendorf M. W. Delta-opioid receptor immunoreactivity: distribution in brainstem and spinal cord, and relationship to biogenic amines and enkephalin. J. Neurosci. 15:1995;1215-1235.
4. Aston-Jones G., Rajkowski J., Kubiak P., Alexinsky T. Locus coeruleus neurons in monkey are selectively activated by attended cues in a vigilance task. J. Neurosci. 14:1994;4467-4480.
5. Bare L. A., Mansson E., Yang D. Expression of two variants of the human mu opioid receptor mRNA in SK-N-SH cells and human brain. Fedn Eur. biochem. Socs Lett. 354:1994;213-216.
6. Barg J., Belcheva M., Rowinski J., Ho A., Burke W. J., Chung H. D., Schmidt C. A., Coscia C. J. Opioid receptor density changes in Alzheimer amygdala and putamen. Brain Res. 632:1993;209-215.
7. Barton A. J., Pearson R. C., Najlerahim A., Harrison P. J. Pre- and postmortem influences on brain RNA. J. Neurochem. 61:1993;1-11.
8. Beaulieu J., Champagne D., Drolet G. Enkephalin innervation of the paraventricular nucleus of the hypothalamus: distribution of fibers and origins of input. J. chem. Neuroanat. 10:1996;79-92.
9. Bellissant E., Denolle T., Sinnassamy P., Bichet D. G., Giudicelli J. F., Lecoz F., Gandon J. M., Allain H. Systemic and regional hemodynamic and biological effects of a new kappa-opioid agonist, niravoline, in healthy volunteers. J. Pharmac. exp. Ther. 278:1996;232-242.
10. Benkert O., Wetzel H., Szegedi A. Serotonin dysfunction syndromes: a functional common denominator for classification of depression, anxiety, and obsessive-compulsive disorder. Int. clin. Psychopharmac. 8:1993;3-14.
11. Berger P. A., Watson S. J., Akil H., Barchas J. D. The effects of naloxone in chronic schizophrenia. Am. J. Psychiat. 138:1981;913-918.
12. Bernard V., Normand E., Bloch B. Phenotypical characterization of the rat striatal neurons expressing muscarinic receptor genes. J. Neurosci. 12:1992;3591-3600.
13. Bicknell R. J. Endogenous opioid peptides and hypothalamic neuroendocrine neurones. J. Endocr. 107:1985;437-446.
14. Bicknell R. J., Leng G. Endogenous opiates regulate oxytocin but not vasopressin secretion from the neurohypophysis. Nature. 298:1982;161-162.
15. Bills L. J., Kreisler K. Treatment of flashbacks with naltrexone.[letter]. Am. J. Psychiat. 150:1993;1430.
16. Blackburn T. P., Cross A. J., Hille C., Slater P. Autoradiographic localization of delta opiate receptors in rat and human brain. Neuroscience. 27:1988;497-506.
17. Bligh J. The thermosensitivity of the hypothalamus and thermoregulation in mammals. Biol. Rev. Camb. phil. Soc. 41:1966;317-368.
18. Bramham C. R., Sarvey J. M. Endogenous activation of mu and delta-1 opioid receptors is required for long-term potentiation induction in the lateral perforant path: dependence on GABAergic inhibition. J. Neurosci. 16:1996;8123-8131.
19. Burke W. J., KL O. M., Chung H. D., Harmon S. K., Miller J. P., Berg L. Effect of pre- and postmortem variables on specific mRNA levels in human brain. Molec. Brain Res. 11:1991;37-41.
20. 11C]diprenorphine PET study. Brain. 118:1995;951-958.
21. Calogero A. E., Scaccianoce S., Burrello N., Nicolai R., Muscolo L. A., Kling M. A., Angelucci L., R D. A. The kappa-opioid receptor agonist MR-2034 stimulates the rat hypothalamic-pituitary-adrenal axis: studies in vivo and in vitro. J. Neuroendocr. 8:1996;579-585.
22. Chaillet P., Marcais-Collado H., Costentin J. Catatonic or hypotonic immobility induced in mice by intracerebroventricular injection of mu or kappa opioid receptor agonists as well as enkephalins or inhibitors of their degradation. Life Sci. 33:1983;2105-2111.
23. Chen Y., Mestek A., Liu J., Hurley J. A., Yu L. Molecular cloning and functional expression of a mu-opioid receptor from rat brain. Molec. Pharmac. 44:1993;8-12.
24. Chiodera P., Coiro V. Endogenous opioid mediation of somatostatin inhibition of arginine vasopressin release evoked by insulin-induced hypoglycemia in man. J. neural Transm. 83:1991;121-126.
25. Clark J. M., Clark A. J., Bartle A., Winn P. The regulation of feeding and drinking in rats with lesions of the lateral hypothalamus made by N-methyl-D-aspartate. Neuroscience. 45:1991;631-640.
26. Cohen G. A., Doze V. A., Madison D. V. Opioid inhibition of GABA release from presynaptic terminals of rat hippocampal interneurons. Neuron. 9:1992;325-335.
27. Cohen M. R., Cohen R. M., Pickar D., Kreger D., Mclellan C., Murphy D. L. Hormonal effects of high dose naloxone in humans. Neuropeptides. 6:1985;373-380.
28. Cox K. H., Deleon D. V., Angerer L. M.et al. Detection of mRNAs in sea urchin embryos by in situ hybridization using asymetric RNA probes. Devl Biol. 101:1984;485-502.
29. Cui Y., Lee T., Wang L. C. Species difference in the modulatory effect of kappa agonist on 5-HT release from ground squirrel and rat hippocampus. Neurosci. Lett. 175:1994;126-128.
30. Dado R. J., Law P. Y., Loh H. H., Elde R. Immunofluorescent identification of a delta (delta)-opioid receptor on primary afferent nerve terminals. NeuroReport. 5:1993;341-344.
31. De Zwaan M., Mitchell J. E. Opiate antagonists and eating behaviour in humans: a review. J. clin. Pharmac. 32:1992;1060-1072.
32. Delay-Goyet P., Zajac J. M., Javoy-Agid F., Agid Y., Roques B. P. Regional distribution of mu, delta and kappa opioid receptors in human brains from controls and parkinsonian subjects. Brain Res. 414:1987;8-14.
33. Delfs J. M., Kong H., Mestek A., Chen Y., Yu L., Reisine T., Chesselet M. F. Expression of mu opioid receptor mRNA in rat brain: an in situ hybridization study at the single cell level. J. comp. Neurol. 345:1994;46-68.
34. Di Chiara G., Imperato A. Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J. Pharmac. exp. Ther. 244:1988;1067-1080.
35. Dolberg O. T., Iancu I., Sasson Y., Zohar J. The pathogenesis and treatment of obsessive-compulsive disorder. Clin. Neuropharmac. 19:1996;129-147.
36. Drouva S. V., Epelbaum J., Tapia-Arancibia L., Laplante E., Kordon C. Opiate receptors modulate LHRH and SRIF release from mediobasal hypothalamic neurons. Neuroendocrinology. 32:1981;163-167.
37. Dykstra L. A., Gmerek D. E., Winger G., Woods J. H. Kappa opioids in rhesus monkeys. I. Diuresis, sedation, analgesia and discriminative stimulus effects. J. Pharmac. exp. Ther. 242:1987;413-420.
38. Ehbehani M. M., Jiang M. R., Chandler S. D., Ennis M. The effect of GABA and its antagonists on midbrain periaqueductal grey neurons in the rat. Pain. 40:1990;195-204.
39. Ellingboe J., Veldhuis J. D., Mendelson J. H., Kuehnle J. C., Mello N. K. Effect of endogenous opioid blockade on the amplitude and frequency of pulsatile luteinizing hormone secretion in normal men. J. clin. Endocr. Metab. 54:1982;854-857.
40. Elliott J., Smart D., Lambert D. G., Traynor J. R. Characterisation of mu-opioid receptors on SH-SY5Y cells using naloxonazine and beta-funaltrexamine. Eur. J. Pharmac. 268:1994;447-450.
41. Evans C. J., Keith D. E. Jr., Morrison H., Magendzo K., Edwards R. H. Cloning of a delta opioid receptor by functional expression. Science. 258:1992;1952-1955.
42. Feuerstein T. J., Gleichauf O., Peckys D., Landwehrmeyer G. B., Scheremet R., Jackisch R. Opioid receptor-mediated control of acetylcholine release in human neocortex tissue. Naunyn-Schmiedeberg's Arch. Pharmac. 354:1996;586-592.
43. Fukuda M., Ono T., Nakamura K. Functional relations among inferotemporal cortex, amygdala, and lateral hypothalamus in monkey operant feeding behaviour. J. Neurophysiol. 57:1987;1060-1077.
44. Gabilondo A. M., Meana J. J., Barturen F., Sastre M., Garcia-Sevilla J. A. Mu-opioid receptor and alpha 2-adrenoceptor agonist binding sites in the postmortem brain of heroin addicts. Psychopharmacology, Berlin. 115:1994;135-140.
45. Gabilondo A. M., Meana J. J., Garcia-Sevilla J. A. Increased density of mu-opioid receptors in the postmortem brain of suicide victims. Brain Res. 682:1995;245-250.
46. Gaveriauxruff C., Peluso J., Befort K., Simonin F., Zilliox C., Kieffer B. L. Detection of opioid receptor mRNA by RT-PCR reveals alternative splicing for the delta- and kappa-opioid receptors. Molec. Brain Res. 48:1997;298-304.
47. Genazzani A. D., Gastaldi M., Petraglia F., Battaglia C., Surico N., Volpe A., Genazzani A. R. Naltrexone administration modulates the neuroendocrine control of luteinizing hormone secretion in hypothalamic amenorrhoea. Hum. Reprod. 10:1995;2868-2871.
48. George S. R., Zastawny R. L., Briones-Urbina R., Cheng R., Nguyen T., Heiber M., Kouvelas A., Chan A. S., BF O. D. Distinct distributions of mu, delta and kappa opioid receptor mRNA in rat brain. Biochem. biophys Res. Commun. 205:1994;1438-1444.
49. Gerfen C. R. Substance P (neurokinin-1) receptor mRNA is selectively expressed in cholinergic neurons in the striatum and basal forebrain. Brain Res. 556:1991;165-170.
50. Gerfen C. R. The neostriatal mosaic: multiple levels of compartmental organization in the basal ganglia. A. Rev. Neurosci. 15:1992;285-320.
51. Greenwald M. K., Stitzer M. L., Haberny K. A. Human pharmacology of the opioid neuropeptide dynorphin a(1-13). J. Pharmac. exp. Ther. 281:1997;1154-1163.
52. Grossman A. Brain opiates and neuroendocrine function. Clinics Endocr. Metab. 12:1983;725-746.
53. Guttenberg N. D., Klop H., Minami M., Satoh M., Voorn P. Co-localization of mu opioid receptor is greater with dynorphin than enkephalin in rat striatum. NeuroReport. 7:1996;2119-2124.
54. Haber S. N., Kowall N. W., Vonsattel J. P., Bird E. D., Richardson E. P. Jr. Gilles de la Tourette's syndrome. A postmortem neuropathological and immunohistochemical study. J. neurol. Sci. 75:1986;225-241.
55. Hagan R. M., Hughes I. E. Opioid receptor sub-types involved in the control of transmitter release in cortex of the brain of the rat. Neuropharmacology. 23:1984;491-495.
56. Hajos M., Greenfield S. A. Synaptic connections between pars compacta and pars reticulata neurones: electrophysiological evidence for functional modules within the substantia nigra. Brain Res. 660:1994;216-224.
57. Hanks G. W., WM O. N., Simpson P., Wesnes K. The cognitive and psychomotor effects of opioid analgesics. II. A randomized controlled trial of single doses of morphine, lorazepam and placebo in healthy subjects. Eur. J. clin. Pharmac. 48:1995;455-460.
58. Harrison P. J., Procter A. W., Barton A. J., Lowe S. L., Najlerahim A., Bertolucci P. H., Bowen D. M., Pearson R. C. Terminal coma affects messenger RNA detection in post mortem human temporal cortex. Molec. Brain Res. 9:1991;161-164.
59. Henry B., Brotchie J. M. Potential of opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson's disease. Drugs Aging. 9:1996;149-158.
60. Herkenham M. Mismatches between neurotransmitter and receptor localizations in brain: observations and implications. Neuroscience. 23:1987;1-38.
61. Herkenham M., Pert C. B. In vitro autoradiography of opiate receptors in rat brain suggests loci of "opiatergic" pathways. Proc. natn. Acad. Sci. U.S.A. 77:1980;5532-5536.
62. Herkenham M., Rice K. C., Jacobson A. E., Rothman R. B. Opiate receptors in rat pituitary are confined to the neural lobe and are exclusively kappa. Brain Res. 382:1986;365-371.
63. Hill M. P., Brotchie J. M. Modulation of glutamate release by a kappa-opioid receptor agonist in rodent and primate striatum. Eur. J. Pharmac. 281:1995;R1-R2.
64. Hiller J. M., Fan L. Q. Laminar distribution of the multiple opioid receptors in the human cerebral cortex. Neurochem. Res. 21:1996;1333-1345.
65. Hiller J. M., Fan L. Q., Simon E. J. Autoradiographic comparison of [3H]DPDPE and [3H]DSLET binding: evidence for distinct delta 1 and delta 2 opioid receptor populations in rat brain. Brain Res. 719:1996;85-95.
66. Hiller J. M., Itzhak Y., Simon E. J. Selective changes in mu, delta and kappa opioid receptor binding in certain limbic regions of the brain in Alzheimer's disease patients. Brain Res. 406:1987;17-23.
67. Hommer D. W., Pert A. The actions of opiates in the rat substantia nigra: an electrophysiological analysis. Peptides. 4:1983;603-608.
68. Howell L. L., Bergman J., Morse W. H. Effects of levorphanol and several kappa-selective opioids on respiration and behaviour in rhesus monkeys. J. Pharmac. exp. Ther. 245:1988;364-372.
69. Hurd Y. L. Differential messenger RNA expression of prodynorphin and proenkephalin in the human brain. Neuroscience. 72:1996;767-783.
70. Hurd Y. L., Brown E. E., Finlay J. M., Fibiger H. C., Gerfen C. R. Cocaine self-administration differentially alters mRNA expression of striatal peptides. Molec. Brain Res. 13:1992;165-170.
71. Hurd Y. L., Herkenham M. Molecular alterations in the neostriatum of human cocaine addicts. Synapse. 13:1993;357-369.
72. Hurd Y. L., Herkenham M. The human neostriatum shows compartmentalization of neuropeptide gene expression in dorsal and ventral regions: an in situ hybridization histochemical analysis. Neuroscience. 64:1995;571-586.
73. Hurd Y. L., Kieffer B., Brady L., Sedvall G. mRNA expression of prodynorphin, proenkephalin and respective opioid receptors in the human brain. Soc. Neurosci. Abstr. 21:1995;148.2.
74. Ikeda M., Mackay K. B., Dewar D., McCulloch J. Differential alterations in adenosine A1 and kappa 1 opioid receptors in the striatum in Alzheimer's disease. Brain Res. 616:1993;211-217.
75. Ikeda T., Kurz A., Sessler D. I., Go J., Kurz M., Belani K., Larson M., Bjorksten A. R., Dechert M., Christensen R. The effect of opioids on thermoregulatory responses in humans and the special antishivering action of meperidine. Ann. N. Y. Acad. Sci. 813:1997;792-798.
76. Iwamoto E. T. Locomotor activity and antinociception after putative mu, kappa and sigma opioid receptor agonists in the rat: influence of dopaminergic agonists and antagonists. J. Pharmac. exp. Ther. 217:1981;451-460.
77. Jacobson S., Trojanowski J. Q. Corticothalamic neurons and thalamocortical terminal fields: an investigation in rat using horseradish peroxidase and autoradiography. Brain Res. 85:1975;385-401.
78. Jenkins P. J., Grossman A. The control of the gonadotrophin releasing hormone pulse generator in relation to opioid and nutritional cues. Hum. Reprod. 8:1993;154-161.
79. Jiang Z. G., North R. A. Pre- and postsynaptic inhibition by opioids in rat striatum. J. Neurosci. 12:1992;356-361.
80. Johnson M. R., Lydiard R. B., Ballenger J. C. Panic disorder. Pathophysiology and drug treatment. Drugs. 49:1995;328-344.
81. Johnson R. D. Opioid involvement in feeding behaviour and the pathogenesis of certain eating disorders. Med. Hypotheses. 45:1995;491-497.
82. Jordan D., Tafani J. A., Ries C., Zajac J. M., Simonnet G., Martin D., Kopp N., Allard M. Evidence for multiple opioid receptors in the human posterior pituitary. J. Neuroendocr. 8:1996;883-887.
83. Jorm C. M., Stamford J. A. Actions of morphine on noradrenaline efflux in the rat locus coeruleus are mediated via both opioid and alpha 2 adrenoceptor mechanisms. Br. J. Anaesth. 74:1995;73-78.
84. Kanof P. D., Handelsman L., Aronson M. J., Ness R., Cochrane K. J., Rubinstein K. J. Clinical characteristics of naloxone-precipitated withdrawal in human opioid-dependent subjects. J. Pharmac. exp. Ther. 260:1992;355-363.
85. Kerr B., Hill H., Coda B., Calogero M., Chapman C. R., Hunt E., Buffington V., Mackie A. Concentration-related effects of morphine on cognition and motor control in human subjects. Neuropsychopharmacology. 5:1991;157-166.
86. Kesner J. S., Kaufman J. M., Wilson R. C., Kuroda G., Knobil E. The effect of morphine on the electrophysiological activity of the hypothalamic luteinizing hormone-releasing hormone pulse generator in the rhesus monkey. Neuroendocrinology. 43:1986;686-688.
87. Khachaturian H., Lewis M. E., Haber S. N., Akil H., Watson S. J. Proopiomelanocortin peptide immunocytochemistry in rhesus monkey brain. Brain Res. Bull. 13:1984;785-800.
88. Kieffer B. L., Befort K., Gaveriaux-Ruff C., Hirth C. G. The delta-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization.[published erratum appears in Proc. natn. Acad. Sci. U.S.A. 1994 Feb 1; 91(3):1193]. Proc. natn. Acad. Sci. U.S.A. 89:1992;12048-12052.
89. Kim H. S., Iyengar S., Wood P. L. Reversal of the actions of morphine on mesocortical dopamine metabolism in the rat by the kappa agonist MR-2034: tentative mu-2 opioid control of mesocortical dopaminergic projections. Life Sci. 41:1987;1711-1715.
90. Kim K. W., Eun Y. A., Soh S. M., Eun J. S., Cho K. P. Ligand binding profiles of U-69,593-sensitive and-insensitive sites in human cerebral cortex membranes: evidence of kappa opioid receptors heterogeneity. Life Sci. 58:1996;1671-1679.
91. Klausner J. M., Caspi J., Lelcuk S., Khazam A., Marin G., Hechtman H. B., Rozin R. R. Delayed muscular rigidity and respiratory depression following fentanyl anesthesia. Archs Surg. 123:1988;66-67.
92. Knapp R. J., Malatynska E., Collins N., Fang L., Wang J. Y., Hruby V. J., Roeske W. R., Yamamura H. I. Molecular biology and pharmacology of cloned opioid receptors. Fedn Am. Socs exp. Biol. J. 9:1995;516-525.
93. Knapp R. J., Malatynska E., Fang L., Li X., Babin E., Nguyen M., Santoro G., Varga E. V., Hruby V. J., Roeske W. R.et al. Identification of a human delta opioid receptor: cloning and expression. Life Sci. 54:1994;PL463-PL469.
94. Koob G. F. Neural mechanisms of drug reinforcement. Ann. N. Y. Acad. Sci. 654:1992;171-191.
95. Kumor K. M., Haertzen C. A., Johnson R. E., Kocher T., Jasinski D. Human psychopharmacology of ketocyclazocine as compared with cyclazocine, morphine and placebo. J. Pharmac. exp. Ther. 238:1986;960-968.
96. Le Moine C., Kieffer B., Gaveriaux-Ruff C., Befort K., Bloch B. Delta-opioid receptor gene expression in the mouse forebrain: localization in cholinergic neurons of the striatum. Neuroscience. 62:1994;635-640.
97. Leander J. D., Zerbe R. L., Hart J. C. Diuresis and suppression of vasopressin by kappa opioids: comparison with mu and delta opioids and clonidine. J. Pharmac. exp. Ther. 234:1985;463-469.
98. Lewis M. E., Khachaturian H., Akil H., Watson S. J. Anatomical relationship between opioid peptides and receptors in rhesus monkey brain. Brain Res. Bull. 13:1984;801-812.
99. Li S., Pelletier G. Opioid regulation of gonadotropin-releasing hormone gene expression in the male rat brain as studied by in situ hybridization. NeuroReport. 4:1993;331-333.
100. Li S., Zhu J., Chen C., Chen Y. W., Deriel J. K., Ashby B., Liu-Chen L. Y. Molecular cloning and expression of a rat kappa opioid receptor. Biochem. J. 295:1993;629-633.
101. Lord J. A., Waterfield A. A., Hughes J., Kosterlitz H. W. Endogenous opioid peptides: multiple agonists and receptors. Nature. 267:1977;495-499.
102. Mackay K. B., Dewar D., McCulloch J. Kappa-1 opioid receptors of the temporal cortex are preserved in Alzheimer's disease. J. neural Transm. 7:1994;73-79.
103. Madison D. V., Nicoll R. A. Enkephalin hyperpolarizes interneurones in the rat hippocampus. J. Physiol. 398:1988;123-130.
104. Maillard C. A., Edwards D. A. Excitotoxin lesions of the zona incerta/lateral tegmentum continuum: effects on male sexual behaviour in rats. Behav. Brain Res. 46:1991;143-149.
105. Maldonado R., Saiardi A., Valverde O., Samad T. A., Roques B. P., Borrelli E. Absence of opiate rewarding effects in mice lacking dopamine D2 receptors. Nature. 388:1997;586-589.
106. Maneuf Y. P., Mitchell I. J., Crossman A. R., Woodruff G. N., Brotchie J. M. Functional implications of kappa opioid receptor-mediated modulation of glutamate transmission in the output regions of the basal ganglia in rodent and primate models of Parkinson's disease. Brain Res. 683:1995;102-108.
107. Mansour A., Burke S., Pavlic R. J., Akil H., Watson S. J. Immunohistochemical localization of the cloned kappa 1 receptor in the rat CNS and pituitary. Neuroscience. 71:1996;671-690.
108. Mansour A., Fox C. A., Akil H., Watson S. J. Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci. 18:1995;22-29.
109. Mansour A., Fox C. A., Burke S., Akil H., Watson S. J. Immunohistochemical localization of the cloned mu opioid receptor in the rat CNS. J. chem. Neuroanat. 8:1995;283-305.
110. Mansour A., Fox C. A., Burke S., Meng F., Thompson R. C., Akil H., Watson S. J. Mu, delta, and kappa opioid receptor mRNA expression in the rat CNS: an in situ hybridization study. J. comp. Neurol. 350:1994;412-438.
111. Mansour A., Fox C. A., Meng F., Akil H., Watson S. J. Kappa 1 receptor mRNA distribution in the rat CNS: comparison to kappa receptor binding and prodynorphin mRNA. Molec. cell. Neurosci. 5:1994;124-144.
112. Mansour A., Fox C. A., Thompson R. C., Akil H., Watson S. J. mu-Opioid receptor mRNA expression in the rat CNS: comparison to mu-receptor binding. Brain Res. 643:1994;245-265.
113. Mansour A., Hoversten M. T., Taylor L. P., Watson S. J., Akil H. The cloned mu, delta and kappa receptors and their endogenous ligands: evidence for two opioid peptide recognition cores. Brain Res. 700:1995;89-98.
114. Mansour A., Thompson R. C., Akil H., Watson S. J. Delta opioid receptor mRNA distribution in the brain: comparison to delta receptor binding and proenkephalin mRNA. J. chem. Neuroanat. 6:1993;351-362.
115. Martin G., Nie Z., Siggins G. R. Mu-opioid receptors modulate NMDA receptor-mediated responses in nucleus accumbens neurons. J. Neurosci. 17:1997;11-22.
116. Martin W. R., Eades C. G., Thompson J. A., Huppler R. E., Gilbert P. E. The effects of morphine- and nalorphine-like drugs in the non-dependent and morphine-dependent chronic spinal dog. J. Pharmac. exp. Ther. 197:1976;517-532.
117. Matsumoto M., Yoshioka M., Togashi H., Hirokami M., Tochihara M., Ikeda T., Smith C. B., Saito H. Mu-opioid receptors modulate noradrenaline release from the rat hippocampus as measured by brain microdialysis. Brain Res. 636:1994;1-8.
118. Matthes H. W., Maldonado R., Simonin F., Valverde O., Slowe S., Kitchen I., Befort K., Dierich A., Le Meur M., Dolle P., Tzavara E., Hanoune J., Roques B. P., Kieffer B. L. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene.[see comments]. Nature. 383:1996;819-823.
119. Maurer R., Cortes R., Probst A., Palacios J. M. Multiple opiate receptor in human brain: an autoradiographic investigation. Life Sci. 33:1983;231-234.
120. McCubbin J. A. Stress and endogenous opioids: behavioral and circulatory interactions. Biol. Psychol. 35:1993;91-122.
121. McGeorge A. J., Faull R. L. The organization of the projection from the cerebral cortex to the striatum in the rat. Neuroscience. 29:1989;503-537.
122. McLaughlin S. K., Margolskee R. F. 33P is preferable to 35S for labeling probes used in in situ hybridization. Biotechniques. 15:1993;506-511.
123. Millan M. J., Morris B. J. Long-term blockade of mu-opioid receptors suggests a role in control of ingestive behaviour, body weight and core temperature in the rat. Brain Res. 450:1988;247-258.
124. Minami M., Satoh M. Molecular biology of the opioid receptors: structures, functions and distributions. Neurosci. Res. 23:1995;121-145.
125. Minciacchi D., Granato A., Barbaresi P. Organization of claustro-cortical projections to the primary somatosensory area of primates. Brain Res. 553:1991;309-312.
126. Moore S. D., Madamba S. G., Schweitzer P., Siggins G. R. Voltage-dependent effects of opioid peptides on hippocampal CA3 pyramidal neurons in vitro. J. Neurosci. 14:1994;809-820.
127. Mulder A. H., Wardeh G., Hogenboom F., Frankhuyzen A. L. Kappa- and delta-opioid receptor agonists differentially inhibit striatal dopamine and acetylcholine release. Nature. 308:1984;278-280.
128. Nakagawa I., Omote K., Kitahata L. M., Collins J. G., Murata K. Serotonergic mediation of spinal analgesia and its interaction with noradrenergic systems. Anesthesiology. 73:1990;474-478.
129. Onaka T., Palmer J. R., Yagi K. Norepinephrine depletion impairs neuroendocrine responses to fear but not novel environmental stimuli in the rat. Brain Res. 713:1996;261-268.
130. Onofrio B. M., Yaksh T. L. Intrathecal delta-receptor ligand produces analgesia in man.[letter]. Lancet. 1:1983;1386-1387.
131. Ostrowski N. L., Pert A. Substantia nigra opiate receptors on basal ganglia efferents. Brain Res. Bull. 38:1995;513-523.
132. Palm S., Moenig H., Maier C. Effects of oral treatment with sustained release morphine tablets on hypothalamic-pituitary-adrenal axis. Meth. Find. exp. clin. Pharmac. 19:1997;269-273.
133. Pasternak G. W. Pharmacological mechanisms of opioid analgesics. Clin. Neuropharmac. 16:1993;1-18.
134. Paul D., Bodnar R. J., Gistrak M. A., Pasternak G. W. Different mu receptor subtypes mediate spinal and supraspinal analgesia in mice. Eur. J. Pharmac. 168:1989;307-314.
135. Pearson R. C., Gatter K. C., Brodal P., Powell T. P. The projection of the basal nucleus of Meynert upon the neocortex in the monkey. Brain Res. 259:1983;132-136.
136. Pearson R. C., Gatter K. C., Powell T. P. Retrograde cell degeneration in the basal nucleus in monkey and man. Brain Res. 261:1983;321-326.
137. Pert A., Yaksh T. Sites of morphine induced analgesia in the primate brain: relation to pain pathways. Brain Res. 80:1974;135-140.
138. Pert C. B., Snyder S. H. Opiate receptor: demonstration in nervous tissue. Science. 179:1973;1011-1014.
139. Pfeiffer A., Brantl V., Herz A., Emrich H. M. Psychotomimesis mediated by kappa opiate receptors. Science. 233:1986;774-776.
140. Pfeiffer A., Braun S., Mann K., Meyer H. D., Brantl V. Anterior pituitary hormone responses to a kappa-opioid agonist in man. J. clin. Endocr. Metab. 62:1986;181-185.
141. Pfeiffer A., Pasi A., Mehraein P., Herz A. Opiate receptor binding sites in human brain. Brain Res. 248:1982;87-96.
142. Piccini P., Morrish P. K., Turjanski N., Sawle G. V., Burn D. J., Weeks R. A., Mark M. H., Maraganore D. M., Lees A. J., Brooks D. J. Dopaminergic function in familial Parkinson's disease: a clinical and 18F-dopa positron emission tomography study. Ann. Neurol. 41:1997;222-229.
143. Pilapil C., Welner S., Magnan J., Gauthier S., Quirion R. Autoradiographic distribution of multiple classes of opioid receptor binding sites in human forebrain. Brain Res. Bull. 19:1987;611-615.
144. Quirion R., Pilapil C., Magnan J. Localization of kappa opioid receptor binding sites in human forebrain using [3H]U69,593: comparison with [3H]bremazocine. Cell. molec. Biol. 7:1987;303-307.
145. Raynor K., Kong H., Mestek A., Bye L. S., Tian M., Liu J., Yu L., Reisine T. Characterization of the cloned human mu opioid receptor. J. Pharmac. exp. Ther. 272:1995;423-428.
146. Reddy S. V., Maderdrut J. L., Yaksh T. L. Spinal cord pharmacology of adrenergic agonist-mediated antinociception. J. Pharmac. exp. Ther. 213:1980;525-533.
147. Renno W. M., Mullet M. A., Beitz A. J. Systemic morphine reduces GABA release in the lateral but not in the medial portion of the midbrain periaqueducal grey of the rat. Brain Res. 594:1992;221-232.
148. Rewerski W., Jori A. Bilateral lesion of anterior hypothalamus and regulation of body temperature in rats. Int. J. exp. Med. 16:1967;355-364.
149. Richardson A., Demoliou-Mason C., Barnard E. A. Guanine nucleotide-binding protein-coupled and uncoupled states of opioid receptors and their relevance to the determination of subtypes. Proc. natn. Acad. Sci. U.S.A. 89:1992;10198-10202.
150. Ronken E., Van Muiswinkel F. L., Mulder A. H., Schoffelmeer A. N. Opioid receptor-mediated inhibition of evoked catecholamine release from cultured neurons of rat ventral mesencephalon and locus coeruleus. Eur. J. Pharmac. 230:1993;349-355.
151. Rossi N. F., Brooks D. P. Kappa-opioid agonist inhibition of osmotically induced AVP release: preferential action at hypothalamic sites. Am. J. Physiol. 270:1996;E367-E372.
152. Rothman R. B., Bykov V., Xue B. G., Xu H., De Costa B. R., Jacobson A. E., Rice K. C., Kleinman J. E., Brady L. S. Interaction of opioid peptides and other drugs with multiple kappa receptors in rat and human brain. Evidence for species differences. Peptides. 13:1992;977-987.
153. Russchen F. T., Amaral D. G., Price J. L. The afferent connections of the substantia innominata in the monkey Macaca fascicularis. J. comp. Neurol. 242:1985;1-27.
154. Sahley T. L., Musiek F. E., Nodar R. H. Naloxone blockade of (-)pentazocine-induced changes in auditory function. Ear Hear. 17:1996;341-353.
155. Sambrook J., Fritsch E. F. and Maniatis T. (1989). Molecular Cloning - A Laboratory Manual, Vol. 2, Cold Spring Harbor Laboratory Press, U.S.A.
156. Sannella M. I., Petersen S. L. Dual label in situ hybridization studies provide evidence that luteinizing hormone-releasing hormone neurons do not synthesize messenger ribonucleic acid for mu, kappa, or delta opiate receptors. Endocrinology. 138:1997;1667-1672.
157. Saper C. B. (1990). Cholinergic System. In The Human Nervous System. (ed. Paxinos G.), pp. 1095-1114, Academic, San Diego.
158. Satoh M., Minami M. Molecular pharmacology of the opioid receptors. Pharmac. Ther. 68:1995;343-364.
159. Sawchenko P. E., Swanson L. W. Immunohistochemical identification of neurons in the paraventricular nucleus of the hypothalamus that project to the medulla or to the spinal cord in the rat. J. comp. Neurol. 205:1982;260-272.
160. Seckl J. R., Haddock J. A., Dunne M. J., Lightman S. L. Opioid-mediated inhibition of oxytocin during insulin-induced hypoglycemic stimulation of vasopressin in man. Acta endocr. 118:1988;77-81.
161. Sharif N. A., Hughes J. Discrete mapping of brain mu and delta opioid receptors using selective peptides: quantitative autoradiography, species differences and comparison with kappa receptors. Peptides. 10:1989;499-522.
162. Simmons M. L., Chavkin C. Endogenous opioid regulation of hippocampal function. Int. Rev. Neurobiol. 39:1996;145-196.
163. Simon E. J., Hiller J. M., Edelman I. Stereospecific binding of the potent narcotic analgesic (3H) etorphine to rat brain homogenate. Proc. natn. Acad. Sci. U.S.A. 70:1973;1947-1949.
164. Simonin F., Befort K., Gaveriaux-Ruff C., Matthes H., Nappey V., Lannes B., Micheletti G., Kieffer B. The human delta-opioid receptor: genomic organization, cDNA cloning, functional expression, and distribution in human brain. Molec. Pharmac. 46:1994;1015-1021.
165. Simonin F., Gaveriaux-Ruff C., Befort K., Matthes H., Lannes B., Micheletti G., Mattei M. G., Charron G., Bloch B., Kieffer B. Kappa-opioid receptor in humans: cDna and genomic cloning, chromosomal assignment, functional expression, pharmacology, and expression pattern in the central nervous system. Proc. natn. Acad. Sci. U.S.A. 92:1995;7006-7010.
166. Slizgi G. R., Ludens J. H. Studies on the nature and mechanism of the diuretic activity of the opioid analgesic ethylketocyclazocine. J. Pharmac. exp. Ther. 220:1982;585-591.
167. Sloniewski P., Morys J., Pilgrim C. Stimulation of glucose utilization in the rat claustrum by pain. Folia neuropath. 33:1995;163-168.
168. Spanagel R., Herz A., Shippenberg T. S. Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc. natn. Acad. Sci. U.S.A. 89:1992;2046-2050.
169. Spangler R., Zhou Y., Maggos C. E., Schlussman S. D., Ho A., Kreek M. J. Prodynorphin, proenkephalin and kappa opioid receptor mRNA responses to acute "binge" cocaine. Molec. Brain Res. 44:1997;139-142.
170. Stevens C. W., Seybold V. S. Changes of opioid binding density in the rat spinal cord following unilateral dorsal rhizotomy. Brain Res. 687:1995;53-62.
171. Streisand J. B., Bailey P. L., LeMaire L., Ashburn M. A., Tarver S. D., Varvel J., Stanley T. H. Fentanyl-induced rigidity and unconsciousness in human volunteers. Incidence, duration, and plasma concentrations. Anesthesiology. 78:1993;629-634.
172. Sukhov R. R., Walker L. C., Rance N. E., Price D. L., Young W. S. III Opioid precursor gene expression in the human hypothalamus. J. comp. Neurol. 353:1995;604-622.
173. Tao R., Auerbach S. B. Increased extracellular serotonin in rat brain after systemic or intraraphe administration of morphine. J. Neurochem. 63:1994;517-524.
174. Tepper J. M., Martin L. P., Anderson D. R. GABAA receptor-mediated inhibition of rat substantia nigra dopaminergic neurons by pars reticulata projection neurons. J. Neurosci. 15:1995;3092-3103.
175. Terenius L. Characteristics of the "receptor" for narcotic analgesics in synaptic plasma membrane fraction from rat brain. Acta pharmac. toxicol. 33:1973;377-384.
176. Terman G. W., Wagner J. J., Chavkin C. Kappa opioids inhibit induction of long-term potentiation in the dentate gyrus of the guinea pig hippocampus. J. Neurosci. 14:1994;4740-4747.
177. Teusch L., Scherbaum N., Bohme H., Bender S., Eschmann-Mehl G., Gastpar M. Different patterns of sexual dysfunctions associated with psychiatric disorders and psychopharmacological treatment. Results of an investigation by semistructured interview of schizophrenic and neurotic patients and methadone-substituted opiate addicts. Pharmacopsychiatry. 28:1995;84-92.
178. Thompson R. C., Mansour A., Akil H., Watson S. J. Cloning and pharmacological characterization of a rat mu opioid receptor. Neuron. 11:1993;903-913.
179. Unterwald E. M., Knapp C., Zukin R. S. Neuroanatomical localization of kappa 1 and kappa 2 opioid receptors in rat and guinea pig brain. Brain Res. 562:1991;57-65.
180. Ur E., Wright D. M., Bouloux P. M., Grossman A. The effects of spiradoline (U-62066E), a kappa-opioid receptor agonist, on neuroendocrine function in man. Br. J. Pharmac. 120:1997;781-784.
181. Van Bockstaele E. J., Colago E. E., Cheng P., Moriwaki A., Uhl G. R., Pickel V. M. Ultrastructural evidence for prominent distribution of the mu-opioid receptor at extrasynaptic sites on noradrenergic dendrites in the rat nucleus locus coeruleus. J. Neurosci. 16:1996;5037-5048.
182. van der Kolk B. A., Greenberg M. S., Orr S. P., Pitman R. K. Endogenous opioids, stress induced analgesia, and posttraumatic stress disorder. Psychopharmac. Bull. 25:1989;417-421.
183. Vonkeman H. E., Voorn P., Brady L. S., Berendse H. W., Richfield E. K. Opioid receptor ligand binding in the human striatum: II. Heterogeneous distribution of kappa opioid receptor labelled with [3H]bremazocine. J. comp. Neurol. 374:1996;223-229.
184. Vonsattel J. P. G., Aizawa M. D., Pei Ge E. M.et al. An improved approach to prepare human brains for research. J. Neuropath. exp. Neurol. 54:1995;42-56.
185. Voorn P., Brady L. S., Berendse H. W., Richfield E. K. Densitometrical analysis of opioid receptor ligand binding in the human striatum - I. Distribution of mu opioid receptor defines shell and core of the ventral striatum. Neuroscience. 75:1996;777-792.
186. Wagner J. J., Terman G. W., Chavkin C. Endogenous dynorphins inhibit excitatory neurotransmission and block LTP induction in the hippocampus. Nature. 363:1993;451-454.
187. Wang H., Moriwaki A., Wang J. B., Uhl G. R., Pickel V. M. Ultrastructural immunocytochemical localization of mu opioid receptors and Leu5-enkephalin in the patch compartment of the rat caudate-putamen nucleus. J. comp. Neurol. 375:1996;659-674.
188. Wang J. B., Imai Y., Eppler C. M., Gregor P., Spivak C. E., Uhl G. R. Mu opiate receptor: cDNA cloning and expression. Proc. natn. Acad. Sci. U.S.A. 90:1993;10230-10234.
189. Waters C. M., Peck R., Rossor M., Reynolds G. P., Hunt S. P. Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson's disease and Huntington's chorea. Neuroscience. 25:1988;419-438.
190. Weisskopf M. G., Zalutsky R. A., Nicoll R. A. The opioid peptide dynorphin mediates heterosynaptic depression of hippocampal mossy fibre synapses and modulates long-term potentiation. Nature. 365:1993;188.
191. Werling L. L., Frattali A., Portoghese P. S., Takemori A. E., Cox B. M. Kappa receptor regulation of dopamine release from striatum and cortex of rats and guinea pigs. J. Pharmac. exp. Ther. 246:1988;282-286.
192. White E. L., Hersch S. M. A quantitative study of thalamocortical and other synapses involving the apical dendrites of corticothalamic projection cells in mouse SmI cortex. J. Neurocytol. 11:1982;137-157.
193. Whitnall M. H., Gainer H., Cox B. M., Molineaux C. J. Dynorphin-A-(1-8) is contained within vasopressin neurosecretory vesicles in rat pituitary. Science. 222:1983;1137-1139.
194. Widdowson P. S., Griffiths E. C., Slater P. The effects of opioids in the periaqueductal grey region of rat brain on hind-limb muscle tone. Neuropeptides. 7:1986;251-258.
195. Wilcox J. N. Fundamental principles of in situ hybridization. J. Histochem. Cytochem. 41:1993;1725-1733.
196. Willenbring M. L., Morley J. E., Krahn D. D., Carlson G. A., Levine A. S., Shafer R. B. Psychoneuroendocrine effects of methadone maintenance. Psychoneuroendocrinology. 14:1989;371-391.
197. Xie C. W., Lewis D. V. Endogenous opioids regulate long-term potentiation of synaptic inhibition in the dentate gyrus of rat hippocampus. J. Neurosci. 15:1995;3788-3795.
198. Yaksh T. L. Pharmacology and mechanisms of opioid analgesic activity. Acta anaesth. scand. 41:1997;94-111.
199. Yaksh T. L., Jessell T. M., Gamse R., Mudge A. W., Leeman S. E. Intrathecal morphine inhibits substance P release from mammalian spinal cord in vivo. Nature. 286:1980;155-157.
200. Yamada M., Groshan K., Phung C. T., Yamada M., Hisamitsu T., Richelson E. The expression of mRNA for a kappa opioid receptor in the substantia nigra of Parkinson's disease brain. Molec. Brain Res. 44:1997;12-20.
201. Yasuda K., Raynor K., Kong H., Breder C. D., Takeda J., Reisine T., Bell G. I. Cloning and functional comparison of kappa and delta opioid receptors from mouse brain. Proc. natn. Acad. Sci. U.S.A. 90:1993;6736-6740.
202. Yen S. S., Quigley M. E., Reid R. L., Ropert J. F., Cetel N. S. Neuroendocrinology of opioid peptides and their role in the control of gonadotropin and prolactin secretion. Am. J. Obstet. Gynecol. 152:1985;485-493.
203. Zieglgansberger W., French E. D., Siggins G. R., Bloom F. E. Opioid peptides may excite hippocampal pyramidal neurons by inhibiting adjacent inhibitory interneurons. Science. 205:1979;415-417.
204. Zimprich A., Simon T., Hollt V. Cloning and expression of an isoform of the rat mu opioid receptor (rMOR1B) which differs in agonist induced desensitization from rMOR1. Fedn Eur. biochem. Socs Lett. 359:1995;142-146.
205. Zukin R. S., Eghbali M., Olive D., Unterwald E. M., Tempel A. Characterization and visualization of rat and guinea pig brain kappa opioid receptors: evidence for kappa 1 and kappa 2 opioid receptors. Proc. natn. Acad. Sci. U.S.A. 85:1988;4061-4065.